Drug Information

Drug General Information
Drug ID
D06HBT
Former ID
DNCL001812
Drug Name
LT-1951
Indication Coronary artery disease [ICD9: 410-414, 429.2; ICD10:I20-I25] Phase 1/2 [521773]
Company
Lumen Therapeutics
Formula
C54H110N36O10
PubChem Compound ID
25077438
Target and Pathway
Target(s) Nitric oxide synthase, inducible Target Info Modulator [526624]
BioCyc Pathway Citrulline-nitric oxide cycle
KEGG Pathway Arginine biosynthesis
Arginine and proline metabolism
Metabolic pathways
Calcium signaling pathway
HIF-1 signaling pathway
Peroxisome
Salmonella infection
Pertussis
Leishmaniasis
Chagas disease (American trypanosomiasis)
Toxoplasmosis
Amoebiasis
Tuberculosis
Pathways in cancer
Small cell lung cancer
NetPath Pathway IL1 Signaling Pathway
IL2 Signaling Pathway
Pathway Interaction Database IL12-mediated signaling events
Alpha9 beta1 integrin signaling events
ATF-2 transcription factor network
IL23-mediated signaling events
Signaling mediated by p38-alpha and p38-beta
HIF-1-alpha transcription factor network
Reactome ROS production in response to bacteria
Nitric oxide stimulates guanylate cyclase
WikiPathways Type II interferon signaling (IFNG)
Spinal Cord Injury
AGE/RAGE pathway
Effects of Nitric Oxide
References
Ref 521773ClinicalTrials.gov (NCT00264706) PolyArginine Treated vEiN grafTs (PATENT). U.S. National Institutes of Health.
Ref 526624Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14. Epub 2003 May 12.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.